Insiders at industrial buildings firm NCI Building Systems (NCS) - Get Report recently sold 11% of the company's shares in insider transactions after the stock has run up nicely this year. The sales also come right around the time Clayton Dubilier & Rice, LLC sold about 7 million shares via a registered offering.

The sales included direct disposal of shares owned for a while plus shares sold upon options exercise.

Chairman Norman Chambers exercised options on 85,000 shares and immediately sold them on January 2, representing 21% of his holdings. That followed his December sale of 16,741 shares, which represented 3% of his holdings at the time.

Todd Moore, NCI's EVP and Chief Legal Compliance Officer unloaded 36,000 shares, or 35% of his holdings in December. President of manufacturing John Kudzal exercised 20,000 options and sold them on December 18.

In total, seven insiders recently sold stock representing 11.5% of the company.

In December, NCI priced a public offering of 7,150,000 shares of its common stock on an underwritten basis by investment funds associated with Clayton Dubilier & Rice, LLC, at a price to the public of $19.55 per share. NCI didn't sell any shares in the offering and will not receive any of the proceeds.

More of What's Trending on TheStreet:

NCI share rose 22% in the last three months, and analysts expect it to continue to outperform 9% industry growth. The company says it expects to remain at a 10% growth pace.

Meanwhile in the energy sector, SandRidge's (SD) - Get Report management team may be seeing the writing on the wall about what the future holds for them after investor Carl Icahn turns up the heat in his activist campaign against the company. Its CEO, chief operating officer, and general counsel all sold significant stakes in the company in the first week of January, according to SEC filings.

In a Jan. 9 letter addressed to SandRidge's chairman John Genova, Icahn asserted that Oklahoma City-based SandRidge should replace two board members and agree "extraordinary transactions," including acquisitions, divestitures, and equity issuances, must be approved by a super-majority vote of the board going forward, meaning four out of five directors.

Finally, the company should dissolve its short-term shareholder rights plan, or poison pill, which blocks any one investor from owning more than 10% of the company's shares. Icahn's 13.5% stake was accumulated just before the company put the poison pill into place on Nov. 26.

As SandRidge's largest shareholder, Icahn said it expects to designate one of the new directors, while he feels the right to choose the other open slot should be offered to the company's other four or five largest shareholders.